Safety and immunogenicity of H5N1 vaccine

被引：3
作者：
Authier, F. J. [1 ]
Gherardi, R. K. [1 ]
机构：
[1] Univ Paris 12, Fac Med, Henri Mondor Hosp,AP HP, INSERM,E0011,Reference Ctr Neuromuscular Disorder, F-94000 Creteil, France
来源：
LANCET | 2006年 / 368卷 / 9554期
关键词：
D O I：
10.1016/S0140-6736(06)69891-7
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2209 / 2210
页数：2
相关论文
共 5 条
[1]   Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine:: phase I randomised trial [J].
Bresson, Jean-Louis ;
Perronne, Christian ;
Launay, Odile ;
Gerdil, Catherine ;
Saville, Melanie ;
Wood, John ;
Hoeschler, Katja ;
Zambon, Maria C. .
LANCET, 2006, 367 (9523) :1657-1664
[2]  
Brewer JM, 1999, J IMMUNOL, V163, P6448
[3]   The global impact of vaccines containing aluminium adjuvants [J].
Clements, CJ ;
Griffiths, E .
VACCINE, 2002, 20 :S24-S33
[4]   What are the limits of adjuvanticity? [J].
Del Giudice, G ;
Podda, A ;
Rappuoli, R .
VACCINE, 2001, 20 :S38-S41
[5]   Aluminum inclusion macrophagic myofasciitis: a recently identified condition [J].
Gherardi, RK ;
Authier, FJ .
IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 2003, 23 (04) :699-+
1